

Molecular Design and Synthesis of Small Organic Molecules as Anticancer Targeting Agents

Thesis

Presented by

Mahitab Khaled Abdel Maksoud Sobhy

Bsc. in Pharmaceutical Sciences

Misr International University

2012

Submitted in partial fulfillment of the

Master Degree

In Pharmaceutical Sciences (Pharmaceutical Chemistry)

Under the supervision of

Dr./ Khaled A. M. Abouzid

*Professor of Pharmaceutical Chemistry &
Dean of the Faculty of Pharmacy
University of Sadat City*

Dr./ Nahla A. H. Farag

*Professor & Head of Pharmaceutical
Chemistry Department, Faculty of
Pharmacy
Misr International University*

Dr. / Deena S. M. Lasheen

*Associate professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Ain Shams University*

Faculty of Pharmacy

Ain Shams University

2019

Acknowledgements

*I owe my deepest appreciation and truthful gratitude to **Professor Khaled Abouzid Mohamed Abouzid**, Professor of Pharmaceutical Chemistry & Dean of the Faculty of Pharmacy University of Sadat City, for suggesting the research point, scientific supervision, innovative ideas, immense knowledge, fruitful opinion, invaluable advice, precious suggestions, continuous encouragement and untiring help. I am really sincerely and profoundly indebted to him for his priceless guidance and endless support during the whole work and writing this thesis. He is a dedicated mentor and a role model, I am really honored to get to know an amazing person and mentor like Dr. Khaled.*

*It's also a pleasure to express my sincere appreciation and gratitude to **Professor Nahla Ahmed Hassan**, Professor and Head of Pharmaceutical Chemistry Department, Faculty of Pharmacy, Misr International University, for her continuous encouragement, tremendous support, endless motivation and enthusiasm. I am heartily grateful to her indispensable opinion, real interest, trust, guidance throughout the whole work. Her passion for work and knowledge is the drive that kept me going forward throughout this long way.*

*I owe my deepest appreciation and truthful gratitude to **Dr Deena Samy Mohamed Lasheen**, Associate professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, for her continuous interest, constant guidance and support during all stages of this work and thesis writing.*

*I would like to express my sincere appreciation and deep gratitude to **Dr Samar Mowafy**, Lecturer of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr International University, for helping me in both experimental section and in writing the thesis. Her door was always open for any questions. I am really grateful for her supervision, unfailing support and continuous encouragement. Without her passionate guidance and help throughout every step, this thesis could not have been successfully conducted.*

*I would like to thank my colleague **Dr Mona Mohamed Abdelatty Mohamed**, Assistant Lecturer of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr International University, for being an amazing, helpful lab mate. It was an honor for me to work with you in the same lab.*

Finally, I am profoundly indebted to my parents, my sister, my husband, friends and my bigger family for their endless patience, understanding, encouragement and support all throughout the whole long way.

This work was published in Bioorg. Chem. 89 (2019) 102988.

Bioorganic Chemistry 89 (2019) 102988



Contents lists available at ScienceDirect

Bioorganic Chemistry

journal homepage: www.elsevier.com/locate/bioorg



3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation



Mahitab K. Sobhy^a, Samar Mowafy^a, Deena S. Lasheen^b, Nahla A. Farag^{a,*},
Khaled A.M. Abouzid^{b,c,*}

^a Pharmaceutical Chemistry Department, Faculty of Pharmacy, Miter International University, Km28 Catra-Ismaïla Road (Ahmed Orabi District), Catra, Egypt

^b Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbasia 11566, Catra, Egypt

^c Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt

ABSTRACT

A series of novel 6,7-dihydro-5H-cyclopenta[d]pyrimidine derivatives was successfully designed, synthesized and evaluated as a new chemical scaffold with vascular endothelial growth factor receptor (VEGFR 2) inhibitory activity. Compounds **6c** and **6b** showed enzyme inhibition of 97% and 87% at 10 μ M, respectively, and exhibited potent dose-related VEGFR 2 inhibition with IC_{50} values of 0.85 μ M and 2.26 μ M, respectively. The design of the 6,7-dihydro-5H-cyclopenta[d]pyrimidine scaffold was implemented via consecutive molecular modelling protocols prior to the synthesis and biological evaluation of the derivatives. First, sorafenib was docked in the binding site of VEGFR 2 to study its binding orientation and affinity, followed by the generation of a valid 3D QSAR pharmacophore model for use in the virtual screening of different 3D databases. Structures with promising pharmacophore-based virtual screening results were refined using molecular docking studies in the binding site of VEGFR 2. A novel scaffold was designed by incorporating the results of the pharmacophore model generation and molecular docking studies. The new scaffold showed hydrophobic interactions with the kinase front pocket that may be attributed to increasing residence time in VEGFR 2, which is a key success factor for ligand optimization in drug discovery. Different derivatives of the novel scaffold were validated using docking studies and pharmacophore mapping, where they exhibited promising results as VEGFR 2 inhibitors to be synthesized and biologically evaluated. 6,7-dihydro-5H-cyclopenta[d]pyrimidine is a new scaffold that can be further optimized for the synthesis of promising VEGFR 2 inhibitors.

Contents

List of figures	viii
List of tables	x
List of abbreviations.....	xi
Abstract:	xiii
1. Introduction	1
1.1. Cancer	1
1.2. Etiology of cancer	1
1.3. Mechanism of occurrence of cancer	2
1.4. Cancer therapy	3
1.4.1. Conventional cancer treatments.....	4
1.4.2. Targeted cancer treatments	11
1.5. Protein kinases	12
1.5.1. Overview.....	12
1.5.2. Tyrosine kinases	13
1.5.3. Structural features of tyrosine kinases.....	14
1.5.4. Tyrosine kinase inhibitors.....	18
1.6. RTKs with angiogenic activity: VEGFR pathway	23
1.6.1. Angiogenesis.....	23
1.6.2. Pathways regulating tumor blood supply	24
1.6.3. VEGFR inhibitors	26
2. Research objective.....	37
2.1. Design process based on previously reported SAR and binding interactions of type II inhibitors of VEGFR2	38
2.2. Design of novel VEGFR2 inhibitors using computational techniques.....	40
2.2.1. Molecular docking of sorafenib.....	41

2.2.2. 3D QSAR pharmacophore model generation.....	41
2.2.3. Virtual screening.....	41
2.2.4. Development of target 6,7-dihydro-5 <i>H</i> -cyclopenta[<i>d</i>]pyrimidine scaffold	42
2.2.5. Evaluation of designed compounds using molecular modelling techniques	44
2.2.6. Synthesis of designed compounds.....	45
2.2.7. Biological evaluation	45
3. Results and discussion.....	46
3.1. Molecular modelling.....	46
3.1.1. Molecular docking of sorafenib.....	46
3.1.2. 3D QSAR pharmacophore model generation.....	48
3.1.3. Virtual screening.....	54
3.1.4. Docking studies of virtually screened compounds	54
3.1.5. Design results.....	62
3.1.6. Validation of the designed scaffold of VEGFR2 inhibitors	64
3.2. Chemistry	77
3.2.1. Synthetic schemes adopted to prepare the designed compounds:.....	77
3.2.2. Scheme 1	79
3.2.3. Scheme 2.....	81
3.3. Biological evaluation	85
3.3.1. In vitro VEGFR2 tyrosine kinase inhibitory activity	85
4. Conclusion.....	88
5. Experimental.....	89
5.1. Molecular modelling	89
5.1.1. Molecular docking	89
5.1.2. 3D QSAR pharmacophore model generation and validation	90

5.1.3. Virtual screening.....	90
5.2. Chemistry	92
5.2.1. Materials and instrumentation	92
5.2.2. Synthesis	93
5.3. Biological evaluation	104
5.3.1. In vitro VEGFR2 tyrosine kinase activity	104
6. References	106
المخلص العربي:.....	128

List of figures

Figure 1. Multistep process of cancer development.	2
Figure 2. Mechanism of action of different chemotherapeutic agents used in treatment of cancer.....	6
Figure 3. Protein kinase activation mechanisms through ligand-induced receptor dimerization and tyrosine autophosphorylation	14
Figure 4. Protein kinases binding sites of ATP molecule.....	15
Figure 5. Protein kinase catalytic domain of VEGFR2	16
Figure 6. Binding interactions of the kinase domain of ABL1.	17
Figure 7. Four types of kinase inhibitors.	19
Figure 8. (a) Chemical structure of CI-1040, an example of type III inhibitors. (b) CI-1040 binds to an allosteric pocket adjacent to ATP binding site	22
Figure 9. Representation of VEGFR.....	25
Figure 10. schematic illustration of binding of VEGF ligands to different VEGFRs and their biological effect.....	26
Figure 11. The family of VEGFR and their inhibitors..	27
Figure 12. Illustration of essential structural features and binding interactions of type II kinase inhibitors	39
Figure 13. Work flow for design of novel VEGFR2 inhibitors.....	40
Figure 14. 3D image of hydrogen bonds formed between top hit 2r4b_GW7 (35) and VEGFR2	43
Figure 15. Illustration of the design strategy of the novel scaffold (VI) according to the structure of the three top hits.	44
Figure 16. Molecular docking of sorafenib inside VEGFR2 with PDB code 3WZE.	47

Figure 17. 3D image of the superimposition of the re-docked conformer of sorafenib over the co-crystalized conformer (colored yellow).....	48
Figure 18. The library of T1-15 training set and S1-10 test set of known active VEGFR2 inhibitors used for pharmacophore model generation along with their IC ₅₀ values (μM)	51
Figure 19. The best generated Pharmacophore model with three features.....	51
Figure 20. Sorafenib as reference compound mapped into the best pharmacophore model.....	54
Figure 21. Illustration of design strategy of proposed scaffold (VI) based on structure of top hit compound 2r4b_GW7 (35)	63
Figure 22. Illustration of binding of the proposed scaffold (VI) and sorafenib (13) to the binding regions of VEGFR2	64
Figure 23. 2D image showing hydrogen bonds and hydrophobic interactions of sorafenib and proposed derivatives (VIa-VIe) with the kinase domain of VEGFR2.	67
Figure 24. Mechanism of Thorpe-Ziegler cyclization reaction	81
Figure 25. Assay of compounds (VIb) and (VIc) on VEGFR2 kinase activity.	87

List of tables

Table 1. Tabular column illustrating the details of the ten hypotheses generated using hypoGen algorithm.....	52
Table 2. The experimental and predicted activity values of the training set compounds according to hypothesis 1 along with their fit values.....	53
Table 3. Docking score, hydrogen and hydrophobic interactions of sorafenib and the three top hits with VEGFR2 (PDB code 3WZE), along with their pharmacophore mapping and fit values.....	56
Table 4. Docking results of sorafenib (13) and the three top hits.....	58
Table 5. Docking score, hydrogen bonds and hydrophobic interactions of sorafenib and the proposed derivatives with VEGFR2 (PDB code 3WZE), along with their pharmacophore mapping and fit values	68
Table 6. Docking results of sorafenib and the proposed derivatives (VIa-VIe)	71
Table 7. Percent inhibition of VEGFR2 enzymatic activity achieved by the synthesized compounds at 10 μ M.....	85
Table 8. The IC ₅₀ value of synthesized compounds with high VEGFR2 percent inhibition.	86

List of abbreviations

ABL1: Abelson murine leukemia viral oncogene homolog 1
Ala: Alanine
Asp: Aspartate
ATP: adenosine 5'-triphosphate
Asp: Aspartate
BCR-ABL: fusion between Abelson tyrosine kinase gene and break point cluster gene
BTK: Bruton's tyrosine kinase
CADD: Computer-aided drug design
c-FMS: Colony-stimulating factor-1 receptor
CHARMm: Chemistry at Harvard Macromolecular Mechanics
c-Kit: v-kit (Hardy-Zuckerman 4 feline) sarcoma viral oncogene
c-SRC: Cellular sarcoma (Schmidt-Ruppin A-2) viral oncogene
Cys: Cysteine
DCM: Dichloromethane
DFG: Aspartate- Phenylalanine- glycine
DIPEA: N, N-Diisopropylethylamine
DMF: Dimethyl Formamide
DMSO: Dimethyl sulphoxide
DNA: Deoxyribonucleic acid
EGFR: Epidermal growth factor receptor
ESI-MS: Electrospray ionization mass spectroscopy
FAK: Focal adhesion kinase
FDA: Food and Drug Administration
FGFR: fibroblast growth factor receptor
FLT-3: fms like tyrosine kinase 3
FT-IR: Fourier transform -Infrared
Glu: Glutamate
Gly: Glycine
GTP: Guanosine 5'-Triphosphate
HBA: Hydrogen bond acceptor
HBD: Hydrogen bond donor
His: Histidine
Hrs: Hours
HUVEC: Human umbilical vein endothelial cells
HYP: Hydrophobic
Hz: Hertz
IC₅₀: Half maximal inhibitory concentration
Ile: Isoleucine
Leu: Leucine
Lys: Lysine
MAPK: Mitogen Activated Protein Kinase
MEK: mitogen-activated protein kinase
m.p: Melting point
MHz: Mega hertz

MS: Mass spectroscopy
NMR: Nuclear magnetic resonance
NRTK: Non-receptor tyrosine kinase
PDB: Protein data bank
Pd-C: Palladium on carbon
PDGFR: Platelet derived growth factor receptor
Phe: Phenyl alanine
PIGF: Placental growth factor
ppm: Part per million
3D QSAR: Three Dimensional Quantitative Structure-Activity Relationship
RA: Ring aromatic
Raf: v-raf murine sarcoma viral oncogene
Ras: Rat sarcoma
RET: Rearranged during transfection proto-oncogene
RMS: Root mean square
RMSD: Root mean square deviation
RNA: Ribonucleic acid
rt: Room temperature
RTK: Receptor tyrosine kinase
SAR: Structure activity relationship
TEA: Triethyl amine
THF: Tetrahydrofuran
Tie-2: Tyrosine kinase with immunoglobulin-like and EGF-like domains 2
TLC: Thin layer chromatography
Tp53: Tumor protein 53
UV: Ultra violet
Val: Valine
VEGF: Vascular endothelial growth factor
VEGFR: Vascular endothelial growth factor receptor

Abstract:

Title of thesis:

**“Molecular Design and Synthesis of Small Organic
Molecules as Anticancer Targeting Agents”**

Name of candidate:

Mahitab Khaled Abdel Maksoud Sobhy

*Teaching assistant of pharmaceutical chemistry
Misr International University*

Thesis supervised by:

Prof./ Khaled A. M. Abouzid

*Professor of Pharmaceutical Chemistry &
Dean of the Faculty of Pharmacy
University of Sadat*

Prof./ Nahla A. H. Farag

*Professor of Pharmaceutical Chemistry &
Head of Pharmaceutical Chemistry Department
Misr International University*

Dr. / Deena S. M. Lasheen

*Associate professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Ain Shams University*

Cancer is a collection of complex diseases. It begins when some of normal body cells start to divide and grow out of control, forming a mass or sheet of cells called tumor. It is a major cause of death throughout the world. According to the American Cancer Society, the number of deaths caused by cancer is second only to cardiovascular diseases. Although great strides have been made in the treatment of cancer over the past years, it continues to be a major health concern. Therefore, extensive efforts have been devoted to searching for new therapeutic approaches. The growth of new blood vessels (angiogenesis) is one of the well established hallmarks in the process of carcinogenesis. Vascular endothelial growth factor receptor 2 (VEGFR2) plays an essential role in cancer angiogenesis. Where, targeting VEGFR2 will inhibit angiogenesis causing tumor cell death.

In this study, a novel series of 6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidine derivatives was successfully designed and synthesized as a new chemical scaffold with vascular endothelial growth factor receptor (VEGFR2) inhibitory activity. The design of the novel scaffold was implemented via consecutive molecular modelling protocols; molecular docking, 3D QSAR pharmacophore model generation protocol and virtual screening, and was also focused on the exploration of the previously revealed SAR studies and bioisosteric modifications of lead compounds.

Designed compounds were then synthesized and their structures were confirmed through different spectral and microanalytical data.

The study involved the synthesis of the following unavailable reported intermediates:

1. 1-(4-Nitrophenyl)-3-phenylurea (**Ia**)
2. 1-(3-Choloro-4-methylphenyl)-3-(4-nitrophenyl)urea (**Ib**)
3. 1-(3-Trifluoromethyl-4-chlorophenyl)-3-(4-nitrophenyl)urea (**Ic**)

4. 1-(3-Methoxyphenyl)-3-(4-nitrophenyl)urea (**Id**)
5. 1-(4-Nitrophenyl)-3-(3-(trifluoromethyl)phenyl)urea (**Ie**)
6. 1-(4-Aminophenyl)-3-phenylurea (**Ila**)
7. 1-(4-Aminophenyl)-3-(3-chloro-4-methylphenyl)urea (**Ilb**)
8. 1-(4-Aminophenyl)-3-(3-trifluoromethyl-4-chlorophenyl)urea (**Ilc**)
9. 1-(4-Aminophenyl)-3-(3-methoxyphenyl)urea (**Ild**)
10. 1-(4-Aminophenyl)-3-(3-(trifluoromethyl)phenyl)urea (**Ile**)
11. 2-Aminocyclopent-1-ene carbonitrile (**III**)
12. 4-Chloro-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidine (**V**)
13. 6,7-Dihydro-3*H*-cyclopenta[*d*]pyrimidin-4(5*H*)-one (**IV**)

Furthermore, it has comprised the synthesis and characterization of the following new targeted compounds:

1. 1-(4-(6,7-Dihydro-5*H*-cyclopenta[*d*]pyrimidin-4-ylamino)phenyl)-3-phenylurea (**VIa**)
2. 1-(3-Chloro-4-methylphenyl)-3-(4-(6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-4-ylamino)phenyl)urea (**VIb**)
3. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-4-ylamino)phenyl)urea (**VIc**)
4. 1-(4-(6,7-Dihydro-5*H*-cyclopenta[*d*]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (**VId**)
5. 1-(4-(6,7-Dihydro-5*H*-cyclopenta[*d*]pyrimidin-4-ylamino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea (**VIe**)

The biological evaluation was accomplished through testing of enzyme inhibition activity against VEGFR2 tyrosine kinase. The enzymatic assay was